for Journals by Title or ISSN
for Articles by Keywords
help
Similar Journals
Journal Cover
Nature Reviews Drug Discovery
Journal Prestige (SJR): 10.106
Citation Impact (citeScore): 10
Number of Followers: 394  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
Published by NPG Homepage  [138 journals]
  • Reshma Kewalramani
    • Nature Reviews Drug Discovery, Published online: 12 November 2019; doi:10.1038/d41573-019-00194-6

      Vertex’s goal over much of the past decade has been on treating cystic fibrosis, targeting the dysfunctional CFTR chloride channel at the root of the disease. Following the speedy approval in October of its triple combination therapy Trikafta, nearly 90% of people with cystic fibrosis now stand to benefit from the firm’s CFTR potentiators and correctors. With this landmark success in hand — and the lucrative market it has opened up — the company is now in the process of broadening its horizons. In April 2020, current CMO Reshma Kewalramani will step up to the CEO role to oversee the transition. She spoke with Asher Mullard about the lessons the company has learned from cystic fibrosis drug development and its future R&D plans.Nature Reviews Drug Discovery, Published online: 2019-11-12; doi:10.1038/d41573-019-00194-62019-11-12
      DOI: 10.1038/d41573-019-00194-6
       
  • Cracking KRAS
    • Nature Reviews Drug Discovery, Published online: 12 November 2019; doi:10.1038/d41573-019-00195-5

      Five anti-cancer KRAS inhibitors, with three different modes of action, are in the clinic. More are on the way.Nature Reviews Drug Discovery, Published online: 2019-11-12; doi:10.1038/d41573-019-00195-52019-11-12
      DOI: 10.1038/d41573-019-00195-5
       
  • Synthetic lethality as an engine for cancer drug target discovery
    • Nature Reviews Drug Discovery, Published online: 11 November 2019; doi:10.1038/s41573-019-0046-z

      Genomic screenings have enabled the discovery of synthetic lethal partners as potential drug targets in cancer. This Review discusses how the genetic concept of synthetic lethality paired with CRISPR-based functional genomic screening can be applied to identify additional synthetic lethal pairs as new and druggable cancer targets.Nature Reviews Drug Discovery, Published online: 2019-11-11; doi:10.1038/s41573-019-0046-z2019-11-11
      DOI: 10.1038/s41573-019-0046-z
       
  • Cloud-based data systems in drug regulation: an industry perspective
    • Nature Reviews Drug Discovery, Published online: 11 November 2019; doi:10.1038/d41573-019-00193-7

      Cloud-based systems for data submitted by sponsors to drug regulatory agencies have the potential to accelerate drug development, streamline regulatory review and enhance regulatory decision-making. Here, we provide a vision for integrating cloud-enabled practices in drug regulation globally.Nature Reviews Drug Discovery, Published online: 2019-11-11; doi:10.1038/d41573-019-00193-72019-11-11
      DOI: 10.1038/d41573-019-00193-7
       
  • Treg conversion dampens autoimmunity
    • Nature Reviews Drug Discovery, Published online: 07 November 2019; doi:10.1038/d41573-019-00191-9

      Treg conversion dampens autoimmunityNature Reviews Drug Discovery, Published online: 2019-11-07; doi:10.1038/d41573-019-00191-92019-11-07
      DOI: 10.1038/d41573-019-00191-9
       
  • Double boost for mRNA cancer vaccines
    • Nature Reviews Drug Discovery, Published online: 07 November 2019; doi:10.1038/d41573-019-00192-8

      Double boost for mRNA cancer vaccinesNature Reviews Drug Discovery, Published online: 2019-11-07; doi:10.1038/d41573-019-00192-82019-11-07
      DOI: 10.1038/d41573-019-00192-8
       
  • NIH launches open science Alzheimer initiative
    • Nature Reviews Drug Discovery, Published online: 06 November 2019; doi:10.1038/d41573-019-00187-5

      NIH launches open science Alzheimer initiativeNature Reviews Drug Discovery, Published online: 2019-11-06; doi:10.1038/d41573-019-00187-52019-11-06
      DOI: 10.1038/d41573-019-00187-5
       
  • Arvinas’s PROTACs pass first safety and PK analysis
    • Nature Reviews Drug Discovery, Published online: 06 November 2019; doi:10.1038/d41573-019-00188-4

      Arvinas’s PROTACs pass first safety and PK analysisNature Reviews Drug Discovery, Published online: 2019-11-06; doi:10.1038/d41573-019-00188-42019-11-06
      DOI: 10.1038/d41573-019-00188-4
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 3.231.226.211
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-